Chordate Medical obtains trademark registration for Ozilia in the US
Chordate Medical announces that the United States Patent and Trademark Office (USPTO) has approved the company’s application to register the trademark Ozilia in the...
Aptahem teams up with Hongene
Aptahem, a biotech company developing RNA-based treatments for severe inflammatory conditions, announces a strategic collaboration with Hongene Biotech, a global leader in RNA and...
SynAct Pharma’s resomelagon under clinical evaluation for dengue
An investigator-initiated phase II study has been launched with SynAct Pharma’s lead candidate, resomelagon, in patients with dengue in Brazil. This trial runs in...
Green light to continue Elicera’s CARMA-trial in B-cell lymphoma
Elicera Therapeutics has received the green light from the Data Safety and Monitoring Board (DSMB) to continue its phase I/IIa clinical trial, CARMA, evaluating...
Curasight strengthens the investor base with Curium and Pentwater
Curasight has announced a rights issue aiming to raise approximately 100 million DKK. The company has already secured approximately DKK 65 million in financing,...
CLS not significantly affected by tariffs
Clinical Laserthermia Systems announces that the proposed U.S. tariffs are expected to have minimal impact on the company, despite the fact that its products...
Takeda’s milestone payment strengthens BioInvent’s business model
BioInvent is reinforcing its position as a partner in antibody development. This was made evident as global pharmaceutical giant Takeda has initiated a phase...
Lipum’s COO brings track record in company building and entrepreneurship
Pernilla Abrahamsson has served as COO at Lipum since 2019 and has since played a key role in the company’s operations. Her background includes...
Spago on the increased dose in Tumorad-01
In March, Spago Nanomedical announced that the independent Data Monitoring Committee had recommended a dose escalation in the ongoing phase I/IIa study with the...
Aptahem reports growing buzz around Apta-1
Malmö-based Aptahem recently released detailed plans of their upcoming phase II study with candidate Apta-1, set to prove its multifaceted potential and optimise future...